Bold Science, Bigger Bets: Mathai Mammen on Visionary R&D and Transforming Biopharma

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies.

00:00 Introduction and Guest Background

00:56 Founding Thebans and Career Highlights

01:43 Leadership at Merck and J&J

02:18 Innovative Approaches at Parabilis Medicines

04:09 Defining and Tackling Undruggable Targets

09:27 Multivalent Drug Design and Bispecifics

13:53 AI and Data Science in Drug Development

19:28 Building and Leading World-Class Teams

25:41 The Importance of Holding Conviction as an Entrepreneur

26:25 Learning from Setbacks in the Biotech Industry

30:10 Challenges and Innovations in Drug Development

32:28 Navigating the Ups and Downs of the Biotech Industry

36:02 The Mission and Future of Parabilis

40:35 Personal Reflections and Advice for Entrepreneurs

46:46 Book Recommendations and Closing Thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Mathai Mammen;

LinkedIn: https://www.linkedin.com/in/mathai-mammen/

Website: https://parabilismed.com/

Follow Mike Rea On;

Website: https://www.ideapharma.com/

X: https://x.com/ideapharma

LinkedIn: https://www.linkedin.com/in/bigidea/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/